Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)

NCT07389278 is registered in ClinicalTrials.gov with Sabine Mueller, MD, PhD as lead sponsor.

NCT NCT07389278
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07389278 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Pegylated Arginine Deiminase (ADI-PEG 20) Plus Radiotherapy (RT) and Temozolomide (TMZ) in Children, Adolescents, and Young Adults With Newly Diagnosed High-grade Glioma (HGG)
Lead sponsor
Sabine Mueller, MD, PhD
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
June 1, 2027
Completion date
June 30, 2035
Enrollment
97 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse hemispheric glioma, h3g34 mutant, diffuse midline glioma, h3 k27m-mutant, glioblastoma, high-grade glioma, high-grade glioma (who iii-iv)